Innovent Biologics Inc (1801)

Hong Kong
71.20
-2.30(-3.13%)
  • Volume:
    3,572,567
  • Bid/Ask:
    71.10/71.25
  • Day's Range:
    70.40 - 74.75

1801 Overview

Prev. Close
73.5
Day's Range
70.4-74.75
Revenue
5.86B
Open
73.05
52 wk Range
50.2-107.1
EPS
-1.33
Volume
3,572,567
Market Cap
103.93B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
5,567,124
P/E Ratio
-
Beta
-
1-Year Change
41.48%
Shares Outstanding
1,459,705,497
Next Earnings Date
-
What is your sentiment on Innovent Biologics Inc?
or
Market is currently closed. Voting is open during market hours.

Innovent Biologics Inc Company Profile

Employees
4596
Market
Hong Kong

Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin’s lymphoma, and esophageal carcinoma. The company also engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin’s lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-303, an adalimumab biosimilar for autoimmune diseases; and IBI-305, a bevacizumab biosimilar to treat metastatic colorectal cancer and non-small cell lung cancer. In addition, it develops IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-308, a human monoclonal antibody for lung, esophageal, and gastric cancer, as well as Hodgkin’s lymphoma; and IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further, the company develops IBI-101, an anti-OX40 agonistic antibody for advanced solid tumors; and IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with The University of Texas MD Anderson Cancer Center to co-develop TYVYT, a sintilimab injection; Roche Group for the discovery and development of bispecific antibodies and multiple cell therapies; Ascentage Pharma for joint commercialization of Olverembatinib; NeoCura Bio-Medical Technology Co. Ltd. to study the combination therapy of Sintilimab and neoantigen vaccine NEO_PLIN2101 for cancer treatment; and Eli Lilly and Company, and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, China.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuySellSellStrong SellBuy
Technical IndicatorsStrong BuyBuyStrong SellStrong SellBuy
SummaryStrong BuyNeutralStrong SellStrong SellBuy
  • C Suisse Cuts INNOVENT BIO TP to $90; Rated Outperform
    0
    • M Stanley Assumes INNOVENT BIO Shr Hike in 15 Days; Rated Overweight
      0
      • Daiwa Sees INNOVENT BIO as Sector Top-pick; 1Q Sintilimab Sales In Line
        0
        • UBS Lifts INNOVENT BIO TP to $132.9, Downgrades INNOCARE-B (09969.HK) to ***Neutral*** (Correct)
          0
          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.